FGFR2基因多态性与骨性错颌畸形的关联
本研究通过两阶段病例对照研究(共895人)分析FGFR2基因8个候选SNP与骨性错颌畸形的关联,发现5个SNP与错颌畸形显著相关(均P<0.05),其中rs2162540与骨性II类相关,其余与骨性III类相关。机制实验表明rs2981578和rs10736303通过影响RUNX2和SMAD4结合亲和力及增强子效应调控FGFR2表达,进而影响成骨分化。
要点
- FGFR2是骨性错颌畸形的风险基因,5个SNP与疾病显著相关。
- rs2162540与骨性II类错颌畸形相关,其他4个SNP与骨性III类相关。
- rs2981578和rs10736303通过降低RUNX2/SMAD4结合力下调FGFR2表达。
核心结论
- FGFR2是骨性错颌畸形的风险基因,其多态性通过调控转录表达影响成骨分化。
研究设计与样本
- 两阶段病例对照研究,共纳入895名受试者,阶段1(n=138 I类、111 II类、81 III类),阶段2(n=279 I类、187 II类、99 III类)。
- 筛选并验证FGFR2中8个候选单核苷酸多态性(SNP)。
主要发现
- 5个SNP(rs2162540、rs2981578、rs1078806、rs11200014、rs10736303)与骨性错颌畸形相关(均P<0.05)。
- rs2162540与骨性II类错颌畸形显著相关,其余SNP与骨性III类错颌畸形相关。
- rs2981578和rs10736303的常见基因型包含RUNX2和SMAD4结合位点,次要基因型降低结合亲和力、增强子效应及FGFR2表达水平。
- FGFR2表达在体外正向促进成骨分化。
关键数值与推荐
- 5个SNP与骨性错颌畸形关联的P值均小于0.05。
临床怎么用
- FGFR2多态性可作为骨性错颌畸形的遗传风险标志物,辅助早期风险评估。
- 机制上FGFR2通过RUNX2/SMAD4调控成骨分化,为干预提供潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast growth factor receptor 2 (FGFR2) in craniofacial bones mediates osteoprogenitor proliferation, differentiation, and apoptosis. The distortion of proper craniofacial bone growth may cause class II and class III skeletal malocclusion and result in compromised function and aesthetics. Here, we investigated the association between variations in FGFR2 and skeletal malocclusions. First, 895 subjects were included in a 2-stage case-control study with independent populations (stage 1: n = 138 class I, 111 class II, and 81 class III; stage 2: n = 279 class I, 187 class II, and 99 class III). Eight candidate single-nucleotide polymorphisms (SNPs) in FGFR2 were screened and validated. Five SNPs (rs2162540, rs2981578, rs1078806, rs11200014, and rs10736303) were found to be associated with skeletal malocclusions (all P < 0.05). That is, rs2162540 was significantly associated with skeletal class II malocclusion, while others were associated with skeletal class III malocclusion. Electrophoretic mobility shift assay and chromatin immunoprecipitation analysis showed that the common genotypes of rs2981578 and rs10736303 contained the binding sites of RUNX2 and SMAD4. Compared with the common genotypes, the minor genotypes at these 2 SNPs decreased the binding affinity and enhancer effect of RUNX2 and SMAD4, as well the levels of FGFR2 expression. In addition, FGFR2 expression contributed positively to osteogenic differentiation in vitro. Thus, we identified FGFR2 as a skeletal malocclusion risk gene, and FGFR2 polymorphisms regulated its transcriptional expression and then osteogenic differentiation.
引用
- Jiang Q, Mei L, Zou Y, et al. Genetic Polymorphisms in FGFR2 Underlie Skeletal Malocclusion. J Dent Res. 2019. PMID: 31509720. doi:10.1177/0022034519872951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。